PCOLCE2 has been demonstrated to be a prognostically relevant biomarker for CRC (34–36), gastric cancer (37), bladder cancer (38), head and neck squamous cell carcinoma (39), and thyroid cancer (40). The gene discussed is PCOLCE2; the disease is urinary bladder carcinoma.